Latest news with #Connexa
Business Wire
31-07-2025
- Business
- Business Wire
Nosis Bio Announces Development Candidate Nomination for Lead Fibrosis Program
ALAMEDA, Calif.--(BUSINESS WIRE)-- Nosis Bio, an AI-native biotechnology company pioneering cell-targeted gene silencing, today announced the nomination of its first development candidate (DC) for fibrosis. The milestone marks the company's transition into IND-enabling studies and the advancement of its proprietary targeted delivery and drug design platform into clinical-stage development. Fibrosis affects over 100 million people globally and remains a high-burden, underserved condition that causes progressive scarring of critical organs such as the lungs, kidneys, and heart. Despite its prevalence, the field has seen limited progress, with existing treatments offering only modest efficacy and being constrained by systemic toxicity and poor tolerability. Nosis Bio has designed a new option for patients: a cell-targeted therapeutic that selectively silences fibrotic drivers only in the pathogenic cells responsible for disease. This precision approach enables superior efficacy, a clean safety profile with minimal off-target effects, and a broad therapeutic index that unlocks the potential for long-term treatment and meaningful clinical impact in an area with significant patient need. Key data supporting the DC nomination include: Superior efficacy compared to standard-of-care therapeutics in head-to-head preclinical studies A clean safety profile at 100-fold the anticipated therapeutic dose, with no dose-limiting toxicities observed Demonstrated repeat dosing with no immunogenicity or anti-drug antibody (ADA) generation observed 'This milestone reflects our belief that the future of medicine lies in delivering potent therapeutics precisely to the cells that need them,' said Jim Martineau, CEO and Co-Founder of Nosis Bio. 'Unlike viral or lipid-based approaches, our cell-targeted platform avoids systemic toxicity and immunogenicity, simplifies manufacturing, and expands delivery to tissues and cell types that were previously out of reach. With our lead candidate nominated and a world-class team in place, we're focused on advancing rapidly to the clinic to bring safer, more effective treatments to patients.' Nosis Bio's lead candidate was developed using the company's Connexa platform, an AI-native system designed to overcome key challenges with targeted delivery and drug design. In particular, Connexa has enabled cell-targeted delivery across seven tissues including the lung, kidney, heart, brain, muscle, small intestine, and key immune cell populations. In addition to its program in fibrosis, Nosis is advancing a pipeline of cell-targeted therapeutics in immunology and inflammatory disease and is collaborating with leading pharmaceutical companies to apply its platform broadly across high-value indications. About Nosis Bio Nosis Bio is an AI-native biotechnology company pioneering cell-targeted gene silencing through its proprietary Connexa platform. By integrating physics-informed deep learning, drug design, and a seamlessly connected wet lab platform, Nosis designs medicines to silence disease-causing genes in precise cell types. The approach enables highly specific, safe, redosable, efficacious, and cost-effective therapeutics for diseases with high unmet need. Nosis is backed by leading institutional investors and has ongoing therapeutic collaborations with major pharmaceutical partners. For more information, visit
Scoop
24-06-2025
- Business
- Scoop
How Foreign Direct Investment Is Helping Deliver World Leading Infrastructure In NZ
Foreign direct investment is helping deliver world-class mobile telecommunications infrastructure for New Zealanders, and the approach could unlock major gains across the rest of our infrastructure sector, says a new report by Infrastructure New Zealand and Connexa. 'We constantly talk about reaching an infrastructure nirvana with modern assets providing world-class services and economic and social opportunities for Kiwis,' says Infrastructure New Zealand Chief Executive Nick Leggett. 'The good news is there are people already doing it using innovative delivery methods, components and pipeline certainty.' 'Connexa is a compelling example of how foreign direct investment, enabled by long-term thinking and a committed pipeline, can deliver nation-building infrastructure vital to the lives of New Zealanders. We just have to learn from them; the public good opportunity is huge.' 'Infrastructure development is sometimes thought about in old-fashioned terms, with slow-moving projects and eye-wateringly long timeframes,' says Connexa Chief Executive Rob Berrill. 'But with the right people and partners in place, critical community infrastructure can be delivered at pace and to a world-class standard.' 'Having a start-up mindset, combined with a committed pipeline of projects and experienced investors with a long-term vision, has enabled Connexa to deliver infrastructure in new and better ways.' 'The benefit of being a new company is that we started with a blank canvas and have been able to define our own culture, the way we work, and the kind of people we want to help take us on that journey.' Connexa is New Zealand's largest mobile tower infrastructure company (TowerCo). In February, Spark sold its remaining holding in the company to Canadian global investment group La Caisse, who along with Ontario Teachers' Pension Plan are now co-controlling shareholders, each with a 50% equity stake in Connexa. Titled Delivering Next Generation Infrastructure, the report outlines how Connexa has grown rapidly since 2022 to manage more than 2,500 tower sites, with another 800 new mobile towers planned over the next eight years. The report delivers seven insights that underpin Connexa's success, from the international investment model, forward pipeline and modular design to new approaches to workforce culture and delivery. 'The Connexa experience shows that if we want the best possible infrastructure for our people to earn, learn and lead productive lives we must be open to the benefits of foreign direct investment and willing to embark on new ways of funding, planning and delivering projects,' says Leggett. 'We now must learn to adapt this model to other sectors of our economy - and the wider way we plan, fund, procure and build the infrastructure we need.' Delivering Next Generation Infrastructure: How global investment and local innovation are shaping Aotearoa's digital future – the Connexa story is available here.
NZ Herald
08-06-2025
- General
- NZ Herald
Bethlehem locals oppose 5G tower, feel ignored by Connexa
Some residents on Bethlehem Rd in Tauranga say they feel like 'guinea pigs' as a 5G cell tower is set to go up outside their homes. Connexa says it's a permitted site and the new tower will help ease the strain on other overloaded cell sites, improving service for customers.
